Bio-Works Technologies and Amicogen Inc. of South Korea have concluded their mutual technology transfer project allowing Amicogen to establish local production of agarose resins in South Korea.

As a result, Bio-Works and Amicogen have settled outstanding payables from Bio-Works with outstanding receivables from Amicogen.

The agreement was made public in a press release dated February 17, 2021 in which Bio-Works announced the signing of the licensing agreement with Amicogen.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit www.bio-works.com.

Attachments
Bio-Works and Amicogen have concluded their technology transfer project.

© Modular Finance, source Nordic Press Releases